Brokerages Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target at $45.38

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eighteen analysts that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $45.38.

TNDM has been the subject of a number of analyst reports. The Goldman Sachs Group decreased their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Royal Bank of Canada cut their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Finally, Citigroup lowered Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their target price for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th.

Tandem Diabetes Care Stock Down 0.1 %

NASDAQ TNDM traded down $0.02 on Monday, reaching $20.60. The company had a trading volume of 550,689 shares, compared to its average volume of 1,472,367. The firm has a market capitalization of $1.37 billion, a PE ratio of -10.66 and a beta of 1.45. Tandem Diabetes Care has a 1 year low of $17.64 and a 1 year high of $53.69. The firm has a 50-day moving average of $30.35 and a 200-day moving average of $34.11. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Remove Ads

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.20% of the company's stock.

Institutional Investors Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Connective Capital Management LLC bought a new stake in Tandem Diabetes Care in the fourth quarter worth about $611,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Tandem Diabetes Care by 20.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 177,739 shares of the medical device company's stock worth $6,402,000 after acquiring an additional 30,133 shares in the last quarter. Two Sigma Investments LP raised its position in Tandem Diabetes Care by 4.4% in the fourth quarter. Two Sigma Investments LP now owns 861,188 shares of the medical device company's stock worth $31,020,000 after acquiring an additional 36,475 shares in the last quarter. State of Wyoming raised its position in Tandem Diabetes Care by 95.9% in the fourth quarter. State of Wyoming now owns 2,996 shares of the medical device company's stock worth $108,000 after acquiring an additional 1,467 shares in the last quarter. Finally, Shell Asset Management Co. raised its holdings in Tandem Diabetes Care by 16.9% during the 4th quarter. Shell Asset Management Co. now owns 26,281 shares of the medical device company's stock worth $947,000 after buying an additional 3,803 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.